French Biotech Raises €20M to Make Precision Molecular Diagnostics

Stilla Technologies has raised a €20M Series C round to fund its mission to produce next-generation microchips that make molecular diagnostics more precise and user-friendly than currently available lab technology.

Contributors to the round included Stilla’s existing investors, such as Illumina Ventures, Kurma Partners and Idinvest Partners. Stilla also added the Chinese company TUS-Holdings to its list of shareholders in this round.

By bringing TUS-Holdings on board, we also look to rapidly expand our activities in China and throughout Asia,” stated Rémi Dangla, co-founder and CEO of Stilla Technologies.


The company will use the Series B funds to develop next-generation microchips for carrying out PCR, a ubiquitous technique used in the life sciences industry for tasks such as detecting pathogens and cancer cells, or testing food for contamination. The company is developing a recent form of the technology called digital PCR, a method that is more sensitive than regular PCR, so can better detect rare DNA sequences in a sample. It also makes it easier to measure how much of the sequence is present in a sample.

You have simple to use, cost-effective technology that is PCR, but you don’t have the precision,” Dangla told me. “And on the other hand, you have sequencing, which is a very high end, very powerful tool, but is really high-cost. Digital PCR can fill the gap.

While digital PCR has been in development for years, it hasn’t completely caught on, partly because it has historically been more labor-intensive than regular PCR. 

Stilla is one of a number of companies working to make digital PCR more accessible, such as Bio-Rad and Thermofisher. According to Dangla, Stilla’s microchip is different from the technology of other companies because it is more user-friendly. In addition, the user can detect up to three different DNA sequences at once through three fluorescence channels, but Stilla aims to boost this to six channels. 

The costs of next-generation sequencing have dropped tremendously in the last two decades, making it a progressively more important tool in diagnostics. However, Dangla told me that PCR will remain a vital tool for cheap and quick molecular diagnostics, particularly for monitoring the progress of patients with infections and cancer. “I see a bright future for both technologies,” he concluded.

Image from Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.